Neuroone Financial Statements From 2010 to 2026

NMTC Stock  USD 0.89  0.01  0.56%   
Neuroone Medical's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Neuroone Medical's valuation are provided below:
Gross Profit
-1.2 M
Profit Margin
(0.81)
Market Capitalization
33.9 M
Enterprise Value Revenue
4.1298
Revenue
6.6 M
We have found one hundred twenty available fundamental ratios for Neuroone Medical, which can be analyzed and compared to other ratios and to its peers in the industry. Investors should ensure to check all of Neuroone Medical's last-minute performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. As of February 2, 2026, Market Cap is expected to decline to about 18.9 M. In addition to that, Enterprise Value is expected to decline to about 17.4 M

Neuroone Medical Total Revenue

14.61 Million

Check Neuroone Medical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neuroone Medical's main balance sheet or income statement drivers, such as Interest Expense of 675.2 K, Selling General Administrative of 8.9 M or Total Revenue of 14.6 M, as well as many indicators such as Price To Sales Ratio of 28.9 K, Dividend Yield of 0.0 or Days Sales Outstanding of 62.36. Neuroone financial statements analysis is a perfect complement when working with Neuroone Medical Valuation or Volatility modules.
  
Build AI portfolio with Neuroone Stock
Check out the analysis of Neuroone Medical Correlation against competitors.

Neuroone Medical Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding48.5 M46.2 M13.9 M
Slightly volatile
Total Assets13 M12.4 M4.5 M
Slightly volatile
Short and Long Term Debt Total339 K306.8 K386.3 K
Pretty Stable
Other Current Liabilities1.4 M1.3 M639.8 K
Slightly volatile
Total Current Liabilities1.3 M2.6 M1.4 M
Slightly volatile
Common Stock Total Equity26.8 K25.5 K14.2 K
Slightly volatile
Liabilities And Stockholders Equity13 M12.4 M4.5 M
Slightly volatile
Total Liabilities4.5 M4.3 MM
Slightly volatile
Total Current Assets12.3 M11.8 M4.2 M
Slightly volatile
Common Stock60.4 K57.5 K19.2 K
Slightly volatile
Other Stockholder Equity103.4 M98.5 M35 M
Slightly volatile
Short Term Debt135.1 K142.2 K292.1 K
Very volatile
Accounts Payable583.4 K1.2 M477.8 K
Slightly volatile
Intangible Assets38.4 K40.5 K108.5 K
Slightly volatile
Capital Stock60.4 K57.5 K22.8 K
Slightly volatile
Property Plant And Equipment Net538.8 K591.6 K292.6 K
Slightly volatile

Neuroone Medical Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative8.9 M8.5 M3.8 M
Slightly volatile
Other Operating Expenses19.7 M18.8 M7.1 M
Slightly volatile
Total Operating Expenses14.9 M14.2 M6.1 M
Slightly volatile
Depreciation And Amortization316 K300.9 K102.2 K
Slightly volatile
Research Development3.2 M5.7 M2.4 M
Slightly volatile
Selling And Marketing Expenses219.1 K125.3 K155.3 K
Slightly volatile
Reconciled Depreciation316 K300.9 K103 K
Slightly volatile

Neuroone Medical Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow1.8 M1.7 M1.8 M
Slightly volatile
Total Cash From Financing Activities154.5 K162.6 K3.2 M
Slightly volatile
Depreciation316 K300.9 K98.5 K
Slightly volatile
Change To Netincome2.2 M1.3 M1.4 M
Slightly volatile
Stock Based Compensation1.3 M1.5 M905.9 K
Slightly volatile
Issuance Of Capital StockM11.1 M6.3 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio28.9 K27.5 KK
Very volatile
Days Sales Outstanding62.3643.8878.9411
Slightly volatile
Average Payables15.8 K16.6 K381.7 K
Slightly volatile
Stock Based Compensation To Revenue0.110.121.5541
Very volatile
Capex To Depreciation5.465.2013.5356
Slightly volatile
EV To Sales28.9 K27.5 KK
Very volatile
Inventory Turnover1.472.042.2514
Slightly volatile
Days Of Inventory On Hand224236234
Slightly volatile
Payables Turnover0.330.34610.6478
Slightly volatile
Sales General And Administrative To Revenue16.7412.38.8696
Slightly volatile
Average Inventory2.1 MM677 K
Slightly volatile
Research And Ddevelopement To Revenue3.073.23454.4412
Pretty Stable
Capex To Revenue0.00740.00780.169
Pretty Stable
Cash Per Share0.01140.0120.1782
Slightly volatile
Days Payables OutstandingK1.1 KK
Slightly volatile
Income Quality0.790.41670.701
Very volatile
Intangibles To Total Assets0.910.86550.5171
Slightly volatile
Current Ratio0.00820.00861.5665
Slightly volatile
Receivables Turnover7.598.616.5031
Slightly volatile
Capex Per Share0.04370.04160.0265
Slightly volatile
Average Receivables681.1 K648.6 K192.8 K
Slightly volatile
Revenue Per Share4.0E-44.0E-40.1383
Very volatile
Interest Debt Per Share1.821.73210.4631
Slightly volatile
Debt To Assets7.739.68596.9042
Slightly volatile
Operating Cycle539280327
Slightly volatile
Days Of Payables OutstandingK1.1 KK
Slightly volatile
Ebt Per Ebit1.451.64651.4418
Pretty Stable
Quick Ratio0.00820.00861.3646
Pretty Stable
Net Income Per E B T1.931.681.7056
Slightly volatile
Cash Ratio0.00640.00681.2173
Pretty Stable
Days Of Inventory Outstanding224236234
Slightly volatile
Days Of Sales Outstanding62.3643.8878.9411
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.04351.0323
Slightly volatile
Fixed Asset Turnover22.2221.176.9709
Slightly volatile
Debt Ratio7.739.68596.9042
Slightly volatile
Price Sales Ratio28.9 K27.5 KK
Very volatile
Asset Turnover0.380.40370.723
Slightly volatile

Neuroone Medical Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap18.9 M26.6 M23.9 M
Slightly volatile
Enterprise Value17.4 M29 M22.2 M
Pretty Stable

Neuroone Fundamental Market Drivers

Neuroone Upcoming Events

12th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Neuroone Medical Financial Statements

Neuroone Medical stakeholders use historical fundamental indicators, such as Neuroone Medical's revenue or net income, to determine how well the company is positioned to perform in the future. Although Neuroone Medical investors may analyze each financial statement separately, they are all interrelated. For example, changes in Neuroone Medical's assets and liabilities are reflected in the revenues and expenses on Neuroone Medical's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Neuroone Medical Technologies. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-148.5 K-141.1 K
Total Revenue13.9 M14.6 M
Cost Of Revenue4.5 M4.8 M
Stock Based Compensation To Revenue 0.12  0.11 
Sales General And Administrative To Revenue 12.30  16.74 
Research And Ddevelopement To Revenue 3.23  3.07 
Capex To Revenue 0.01  0.01 
Ebit Per Revenue(41.66)(43.75)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Neuroone Medical Tec offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neuroone Medical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neuroone Medical Technologies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neuroone Medical Technologies Stock:
Check out the analysis of Neuroone Medical Correlation against competitors.
You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Will Health Care Equipment & Supplies sector continue expanding? Could Neuroone diversify its offerings? Factors like these will boost the valuation of Neuroone Medical. Anticipated expansion of Neuroone directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Neuroone Medical data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(0.16)
Revenue Per Share
0.189
Quarterly Revenue Growth
1.054
Return On Assets
(0.45)
Return On Equity
(0.95)
The market value of Neuroone Medical Tec is measured differently than its book value, which is the value of Neuroone that is recorded on the company's balance sheet. Investors also form their own opinion of Neuroone Medical's value that differs from its market value or its book value, called intrinsic value, which is Neuroone Medical's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Neuroone Medical's market value can be influenced by many factors that don't directly affect Neuroone Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Neuroone Medical's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Neuroone Medical should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Neuroone Medical's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.